Kenox has a strong pipeline of innovative and generic aerosol-based drug products (OTC and Rx) in various stages of development.
Our strategy in this realm is to employ our own IP and know-how in formulation and device technology to develop innovative aerosol-based products designed for eye, nasal, oral, and inhalation applications. These niche products allow for the safe and efficacious delivery of molecules previously approved for a different therapeutic indication and/or a different delivery route, for eg, oral tablets and injections (505(b)(2) strategy).
Our strategy for generics includes the development and commercialization of high-quality and cost-effective generic nasal sprays, nebulized solutions, and pMDI products. These products are all currently in different stages of development, with our first product launch scheduled for 2020.